Hyloris Pharmaceuticals SA: Hyloris reports results for the

Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million (€0.2 million in 2020) Significant expansion of commercial footprint of Maxigesic

Related Keywords

Belgium , Norway , Malaysia , Australia , United Kingdom , Luxembourg , Austria , Canada , Woman , Bahrain , Pakistan , Germany , Mexico , Iceland , Thailand , New Zealand , Denmark , Netherlands , Israel , Albania , Italy , Ireland , South Korea , Panama , France , Spain , Cyprus , Greece , Belgian , Thomas Jacobsen , Vaneltix Pharma , Vulvovaginal Candidiasis , Olivier Declercq , Abid Irshad , Jean Luc Vandebroek , Stijn Van Rompay , Chris Buyse , Delveinsight Market Research , Alter Pharma Group , Department Of Radiology , University Of South Carolina College Medicine , Linkedin , Hyloris Pharmaceuticals , Leukemia Lymphoma Society , Academic Pharmaceuticals , Hyloris Pharmaceuticals Sa Euronext Brussels , Business Development , Euronext Brussels , Chief Executive Officer , Delveinsight Market , Domiphen Bromide , Purna Female Healthcare , Recurrent Vulvovaginal Candidiasis , Pleco Therapeutics , Healthcare April , Lymphoma Society , Medical University , South Carolina College , Fusidic Acid Cream , Fusidic Acid , Chief Business Development Officer , Chief Financial Officer , Managing Director , Initial Public , Hyloris , Pharmaceuticals , Reports , Results , Bull , Ear , 021 ,